nodes	percent_of_prediction	percent_of_DWPC	metapath
Gonadorelin—Ceruletide—CCKAR—type 2 diabetes mellitus	0.0284	0.968	CrCbGaD
Gonadorelin—GNRHR—Peptide GPCRs—MC4R—type 2 diabetes mellitus	0.00955	0.0354	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—CCKAR—type 2 diabetes mellitus	0.00662	0.0246	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—AGTR2—type 2 diabetes mellitus	0.00578	0.0215	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—EDNRB—type 2 diabetes mellitus	0.00554	0.0206	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GCGR—type 2 diabetes mellitus	0.0054	0.02	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—EDNRA—type 2 diabetes mellitus	0.00523	0.0194	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GRK5—type 2 diabetes mellitus	0.00497	0.0185	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GCGR—type 2 diabetes mellitus	0.00483	0.0179	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRK5—type 2 diabetes mellitus	0.00445	0.0165	CbGpPWpGaD
Gonadorelin—GNRHR—GPCRs, Other—EDNRA—type 2 diabetes mellitus	0.00443	0.0165	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—MTNR1A—type 2 diabetes mellitus	0.00414	0.0154	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—CCR5—type 2 diabetes mellitus	0.00337	0.0125	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—MTNR1A—type 2 diabetes mellitus	0.00316	0.0117	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—CCKAR—type 2 diabetes mellitus	0.00315	0.0117	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—MC4R—type 2 diabetes mellitus	0.00301	0.0112	CbGpPWpGaD
Gonadorelin—GNRHR—GPCRs, Other—CCR5—type 2 diabetes mellitus	0.00286	0.0106	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—type 2 diabetes mellitus	0.00282	0.0105	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—TRPC6—type 2 diabetes mellitus	0.00277	0.0103	CbGpPWpGaD
Gonadorelin—Asthenia—Tolazamide—type 2 diabetes mellitus	0.00275	0.00392	CcSEcCtD
Gonadorelin—Angiopathy—Bromocriptine—type 2 diabetes mellitus	0.00273	0.0039	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GCGR—type 2 diabetes mellitus	0.00272	0.0101	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.00271	0.00387	CcSEcCtD
Gonadorelin—Pruritus—Chlorpropamide—type 2 diabetes mellitus	0.00271	0.00387	CcSEcCtD
Gonadorelin—Pruritus—Tolazamide—type 2 diabetes mellitus	0.00271	0.00387	CcSEcCtD
Gonadorelin—Breast disorder—Metformin—type 2 diabetes mellitus	0.0027	0.00386	CcSEcCtD
Gonadorelin—Abdominal discomfort—Orlistat—type 2 diabetes mellitus	0.00269	0.00384	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Repaglinide—type 2 diabetes mellitus	0.00265	0.00378	CcSEcCtD
Gonadorelin—Headache—Tolbutamide—type 2 diabetes mellitus	0.00264	0.00376	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Valsartan—type 2 diabetes mellitus	0.00264	0.00376	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—EDNRB—type 2 diabetes mellitus	0.00264	0.00979	CbGpPWpGaD
Gonadorelin—Constipation—Repaglinide—type 2 diabetes mellitus	0.00263	0.00375	CcSEcCtD
Gonadorelin—Diarrhoea—Chlorpropamide—type 2 diabetes mellitus	0.00262	0.00374	CcSEcCtD
Gonadorelin—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.00262	0.00373	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Orlistat—type 2 diabetes mellitus	0.00261	0.00372	CcSEcCtD
Gonadorelin—Diarrhoea—Linagliptin—type 2 diabetes mellitus	0.0026	0.0037	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—HTR2C—type 2 diabetes mellitus	0.00256	0.0095	CbGpPWpGaD
Gonadorelin—Breast disorder—Irbesartan—type 2 diabetes mellitus	0.00255	0.00364	CcSEcCtD
Gonadorelin—Asthenia—Nateglinide—type 2 diabetes mellitus	0.00255	0.00363	CcSEcCtD
Gonadorelin—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.00252	0.00359	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Repaglinide—type 2 diabetes mellitus	0.00251	0.00358	CcSEcCtD
Gonadorelin—Pruritus—Nateglinide—type 2 diabetes mellitus	0.00251	0.00358	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.00251	0.00358	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GIPR—type 2 diabetes mellitus	0.00251	0.00931	CbGpPWpGaD
Gonadorelin—Fatigue—Rosiglitazone—type 2 diabetes mellitus	0.0025	0.00357	CcSEcCtD
Gonadorelin—Nausea—Tolbutamide—type 2 diabetes mellitus	0.0025	0.00357	CcSEcCtD
Gonadorelin—Shock—Glipizide—type 2 diabetes mellitus	0.0025	0.00357	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—EDNRA—type 2 diabetes mellitus	0.00249	0.00925	CbGpPWpGaD
Gonadorelin—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.00248	0.00354	CcSEcCtD
Gonadorelin—Abdominal discomfort—Metformin—type 2 diabetes mellitus	0.00248	0.00354	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—type 2 diabetes mellitus	0.00248	0.0092	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB3—type 2 diabetes mellitus	0.00246	0.00915	CbGpPWpGaD
Gonadorelin—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.00244	0.00348	CcSEcCtD
Gonadorelin—Anaphylactic shock—Pioglitazone—type 2 diabetes mellitus	0.00244	0.00347	CcSEcCtD
Gonadorelin—Abdominal pain—Repaglinide—type 2 diabetes mellitus	0.00243	0.00347	CcSEcCtD
Gonadorelin—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.00243	0.00347	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—GHRL—type 2 diabetes mellitus	0.00243	0.00901	CbGpPWpGaD
Gonadorelin—Upper respiratory tract infection—Metformin—type 2 diabetes mellitus	0.0024	0.00343	CcSEcCtD
Gonadorelin—Headache—Chlorpropamide—type 2 diabetes mellitus	0.0024	0.00342	CcSEcCtD
Gonadorelin—Headache—Tolazamide—type 2 diabetes mellitus	0.0024	0.00342	CcSEcCtD
Gonadorelin—Breast disorder—Losartan—type 2 diabetes mellitus	0.0024	0.00342	CcSEcCtD
Gonadorelin—Erythema—Glyburide—type 2 diabetes mellitus	0.0024	0.00342	CcSEcCtD
Gonadorelin—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	0.00239	0.00341	CcSEcCtD
Gonadorelin—Headache—Linagliptin—type 2 diabetes mellitus	0.00238	0.00339	CcSEcCtD
Gonadorelin—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	0.00237	0.00338	CcSEcCtD
Gonadorelin—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	0.00237	0.00337	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—type 2 diabetes mellitus	0.00236	0.00876	CbGpPWpGaD
Gonadorelin—Vomiting—Acarbose—type 2 diabetes mellitus	0.00234	0.00334	CcSEcCtD
Gonadorelin—Shock—Glimepiride—type 2 diabetes mellitus	0.00234	0.00333	CcSEcCtD
Gonadorelin—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	0.00232	0.00331	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—MC4R—type 2 diabetes mellitus	0.00229	0.00851	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—type 2 diabetes mellitus	0.00229	0.0085	CbGpPWpGaD
Gonadorelin—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.00228	0.00325	CcSEcCtD
Gonadorelin—Nausea—Tolazamide—type 2 diabetes mellitus	0.00228	0.00325	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Irbesartan—type 2 diabetes mellitus	0.00227	0.00323	CcSEcCtD
Gonadorelin—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.00226	0.00323	CcSEcCtD
Gonadorelin—Vomiting—Nateglinide—type 2 diabetes mellitus	0.00226	0.00322	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—type 2 diabetes mellitus	0.00223	0.00827	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GCG—type 2 diabetes mellitus	0.00222	0.00824	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—GIP—type 2 diabetes mellitus	0.00221	0.00819	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.0022	0.00313	CcSEcCtD
Gonadorelin—Nausea—Acarbose—type 2 diabetes mellitus	0.00219	0.00312	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—RASGRP1—type 2 diabetes mellitus	0.00218	0.00811	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—MTNR1B—type 2 diabetes mellitus	0.00218	0.00808	CbGpPWpGaD
Gonadorelin—Pain—Glipizide—type 2 diabetes mellitus	0.00217	0.0031	CcSEcCtD
Gonadorelin—Constipation—Glipizide—type 2 diabetes mellitus	0.00217	0.0031	CcSEcCtD
Gonadorelin—Pruritus—Repaglinide—type 2 diabetes mellitus	0.00217	0.0031	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—type 2 diabetes mellitus	0.00217	0.00806	CbGpPWpGaD
Gonadorelin—Erythema—Gliclazide—type 2 diabetes mellitus	0.00215	0.00307	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Losartan—type 2 diabetes mellitus	0.00213	0.00304	CcSEcCtD
Gonadorelin—Flatulence—Gliclazide—type 2 diabetes mellitus	0.00212	0.00303	CcSEcCtD
Gonadorelin—Nausea—Nateglinide—type 2 diabetes mellitus	0.00211	0.00301	CcSEcCtD
Gonadorelin—Shock—Bromocriptine—type 2 diabetes mellitus	0.00211	0.003	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.0021	0.003	CcSEcCtD
Gonadorelin—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.0021	0.003	CcSEcCtD
Gonadorelin—Fatigue—Pioglitazone—type 2 diabetes mellitus	0.0021	0.003	CcSEcCtD
Gonadorelin—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.0021	0.00299	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCKAR—type 2 diabetes mellitus	0.00209	0.00775	CbGpPWpGaD
Gonadorelin—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.00208	0.00297	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	0.00208	0.00297	CcSEcCtD
Gonadorelin—Angiopathy—Valsartan—type 2 diabetes mellitus	0.00206	0.00294	CcSEcCtD
Gonadorelin—Breast disorder—Ramipril—type 2 diabetes mellitus	0.00206	0.00294	CcSEcCtD
Gonadorelin—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.00206	0.00293	CcSEcCtD
Gonadorelin—Immune system disorder—Valsartan—type 2 diabetes mellitus	0.00205	0.00293	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.00205	0.00292	CcSEcCtD
Gonadorelin—Fatigue—Glimepiride—type 2 diabetes mellitus	0.00205	0.00292	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.00204	0.00291	CcSEcCtD
Gonadorelin—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.00204	0.00291	CcSEcCtD
Gonadorelin—Immune system disorder—Orlistat—type 2 diabetes mellitus	0.00203	0.00289	CcSEcCtD
Gonadorelin—Constipation—Sitagliptin—type 2 diabetes mellitus	0.00202	0.00289	CcSEcCtD
Gonadorelin—Pain—Sitagliptin—type 2 diabetes mellitus	0.00202	0.00289	CcSEcCtD
Gonadorelin—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.00201	0.00287	CcSEcCtD
Gonadorelin—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.00199	0.00283	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—type 2 diabetes mellitus	0.00199	0.00737	CbGpPWpGaD
Gonadorelin—Vomiting—Repaglinide—type 2 diabetes mellitus	0.00195	0.00279	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—type 2 diabetes mellitus	0.00195	0.00725	CbGpPWpGaD
Gonadorelin—Flatulence—Valsartan—type 2 diabetes mellitus	0.00195	0.00278	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.00194	0.00277	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.00193	0.00276	CcSEcCtD
Gonadorelin—Flatulence—Orlistat—type 2 diabetes mellitus	0.00193	0.00275	CcSEcCtD
Gonadorelin—Headache—Repaglinide—type 2 diabetes mellitus	0.00193	0.00275	CcSEcCtD
Gonadorelin—Shock—Glyburide—type 2 diabetes mellitus	0.00193	0.00275	CcSEcCtD
Gonadorelin—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.00192	0.00274	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—GNB3—type 2 diabetes mellitus	0.00191	0.0071	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—AVP—type 2 diabetes mellitus	0.00189	0.00701	CbGpPWpGaD
Gonadorelin—Abdominal discomfort—Ramipril—type 2 diabetes mellitus	0.00189	0.00269	CcSEcCtD
Gonadorelin—Angiopathy—Metformin—type 2 diabetes mellitus	0.00188	0.00268	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—ADRB3—type 2 diabetes mellitus	0.00188	0.00697	CbGpPWpGaD
Gonadorelin—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.00188	0.00268	CcSEcCtD
Gonadorelin—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00187	0.00267	CcSEcCtD
Gonadorelin—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.00187	0.00267	CcSEcCtD
Gonadorelin—Immune system disorder—Metformin—type 2 diabetes mellitus	0.00187	0.00267	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.00185	0.00264	CcSEcCtD
Gonadorelin—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.00185	0.00263	CcSEcCtD
Gonadorelin—Constipation—Bromocriptine—type 2 diabetes mellitus	0.00183	0.00261	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	0.00183	0.00261	CcSEcCtD
Gonadorelin—Nausea—Repaglinide—type 2 diabetes mellitus	0.00183	0.0026	CcSEcCtD
Gonadorelin—Asthenia—Glipizide—type 2 diabetes mellitus	0.00182	0.0026	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—type 2 diabetes mellitus	0.00182	0.00677	CbGpPWpGaD
Gonadorelin—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00182	0.0026	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—CRHR1—type 2 diabetes mellitus	0.00181	0.00673	CbGpPWpGaD
Gonadorelin—Erythema—Metformin—type 2 diabetes mellitus	0.0018	0.00257	CcSEcCtD
Gonadorelin—Pruritus—Glipizide—type 2 diabetes mellitus	0.0018	0.00257	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—EDN1—type 2 diabetes mellitus	0.0018	0.00667	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.0018	0.00256	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—MTNR1A—type 2 diabetes mellitus	0.00178	0.00662	CbGpPWpGaD
Gonadorelin—Flatulence—Metformin—type 2 diabetes mellitus	0.00178	0.00253	CcSEcCtD
Gonadorelin—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.00177	0.00253	CcSEcCtD
Gonadorelin—Immune system disorder—Irbesartan—type 2 diabetes mellitus	0.00176	0.00252	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.00175	0.0025	CcSEcCtD
Gonadorelin—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.00175	0.00249	CcSEcCtD
Gonadorelin—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.00175	0.00249	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRB—type 2 diabetes mellitus	0.00175	0.00648	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00174	0.00249	CcSEcCtD
Gonadorelin—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.00174	0.00248	CcSEcCtD
Gonadorelin—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00173	0.00246	CcSEcCtD
Gonadorelin—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.00172	0.00246	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNB3—type 2 diabetes mellitus	0.00171	0.00635	CbGpPWpGaD
Gonadorelin—Asthenia—Glimepiride—type 2 diabetes mellitus	0.0017	0.00243	CcSEcCtD
Gonadorelin—Erythema—Irbesartan—type 2 diabetes mellitus	0.0017	0.00242	CcSEcCtD
Gonadorelin—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.0017	0.00242	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—HTR2C—type 2 diabetes mellitus	0.0017	0.00629	CbGpPWpGaD
Gonadorelin—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.00169	0.00241	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.00169	0.00241	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—type 2 diabetes mellitus	0.00169	0.00627	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—type 2 diabetes mellitus	0.00169	0.00627	CbGpPWpGaD
Gonadorelin—Pruritus—Glimepiride—type 2 diabetes mellitus	0.00168	0.00239	CcSEcCtD
Gonadorelin—Flatulence—Irbesartan—type 2 diabetes mellitus	0.00168	0.00239	CcSEcCtD
Gonadorelin—Angiopathy—Losartan—type 2 diabetes mellitus	0.00167	0.00238	CcSEcCtD
Gonadorelin—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.00167	0.00238	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—MTNR1B—type 2 diabetes mellitus	0.00166	0.00615	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRA—type 2 diabetes mellitus	0.00165	0.00612	CbGpPWpGaD
Gonadorelin—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.00162	0.00232	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—MTNR1A—type 2 diabetes mellitus	0.00162	0.00601	CbGpPWpGaD
Gonadorelin—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.00162	0.00231	CcSEcCtD
Gonadorelin—Vomiting—Glipizide—type 2 diabetes mellitus	0.00162	0.00231	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GLP1R—type 2 diabetes mellitus	0.00162	0.006	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.00161	0.0023	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRA2A—type 2 diabetes mellitus	0.00161	0.00599	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GHRL—type 2 diabetes mellitus	0.00161	0.00597	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—type 2 diabetes mellitus	0.00161	0.00596	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.0016	0.00228	CcSEcCtD
Gonadorelin—Erythema—Losartan—type 2 diabetes mellitus	0.0016	0.00228	CcSEcCtD
Gonadorelin—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.0016	0.00228	CcSEcCtD
Gonadorelin—Headache—Glipizide—type 2 diabetes mellitus	0.00159	0.00227	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—CCKAR—type 2 diabetes mellitus	0.00159	0.0059	CbGpPWpGaD
Gonadorelin—Shock—Valsartan—type 2 diabetes mellitus	0.00159	0.00227	CcSEcCtD
Gonadorelin—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.00158	0.00226	CcSEcCtD
Gonadorelin—Flatulence—Losartan—type 2 diabetes mellitus	0.00158	0.00225	CcSEcCtD
Gonadorelin—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.00156	0.00223	CcSEcCtD
Gonadorelin—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.00155	0.00221	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—GCGR—type 2 diabetes mellitus	0.00154	0.00571	CbGpPWpGaD
Gonadorelin—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.00154	0.00219	CcSEcCtD
Gonadorelin—Headache—Pioglitazone—type 2 diabetes mellitus	0.00153	0.00218	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00152	0.00216	CcSEcCtD
Gonadorelin—Fatigue—Gliclazide—type 2 diabetes mellitus	0.00152	0.00216	CcSEcCtD
Gonadorelin—Nausea—Glipizide—type 2 diabetes mellitus	0.00151	0.00215	CcSEcCtD
Gonadorelin—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00151	0.00215	CcSEcCtD
Gonadorelin—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.0015	0.00215	CcSEcCtD
Gonadorelin—Pain—Gliclazide—type 2 diabetes mellitus	0.0015	0.00214	CcSEcCtD
Gonadorelin—Constipation—Gliclazide—type 2 diabetes mellitus	0.0015	0.00214	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—AGT—type 2 diabetes mellitus	0.00149	0.00553	CbGpPWpGaD
Gonadorelin—Headache—Glimepiride—type 2 diabetes mellitus	0.00149	0.00212	CcSEcCtD
Gonadorelin—Headache—Sitagliptin—type 2 diabetes mellitus	0.00148	0.00211	CcSEcCtD
Gonadorelin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.00147	0.00209	CcSEcCtD
Gonadorelin—Shock—Metformin—type 2 diabetes mellitus	0.00145	0.00206	CcSEcCtD
Gonadorelin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.00144	0.00206	CcSEcCtD
Gonadorelin—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.00144	0.00206	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.00144	0.00205	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—IAPP—type 2 diabetes mellitus	0.00143	0.00531	CbGpPWpGaD
Gonadorelin—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.00142	0.00203	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—GIPR—type 2 diabetes mellitus	0.00142	0.00526	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GRK5—type 2 diabetes mellitus	0.00142	0.00526	CbGpPWpGaD
Gonadorelin—Nausea—Glimepiride—type 2 diabetes mellitus	0.00141	0.00201	CcSEcCtD
Gonadorelin—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00141	0.002	CcSEcCtD
Gonadorelin—Asthenia—Glyburide—type 2 diabetes mellitus	0.0014	0.002	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GCGR—type 2 diabetes mellitus	0.0014	0.00519	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.00139	0.00199	CcSEcCtD
Gonadorelin—Fatigue—Valsartan—type 2 diabetes mellitus	0.00139	0.00199	CcSEcCtD
Gonadorelin—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.00139	0.00198	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—AGTR2—type 2 diabetes mellitus	0.00139	0.00516	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.00139	0.00198	CcSEcCtD
Gonadorelin—Pruritus—Glyburide—type 2 diabetes mellitus	0.00138	0.00197	CcSEcCtD
Gonadorelin—Constipation—Valsartan—type 2 diabetes mellitus	0.00138	0.00197	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.00138	0.00196	CcSEcCtD
Gonadorelin—Fatigue—Orlistat—type 2 diabetes mellitus	0.00138	0.00196	CcSEcCtD
Gonadorelin—Erythema—Ramipril—type 2 diabetes mellitus	0.00137	0.00196	CcSEcCtD
Gonadorelin—Shock—Irbesartan—type 2 diabetes mellitus	0.00137	0.00195	CcSEcCtD
Gonadorelin—Pain—Orlistat—type 2 diabetes mellitus	0.00136	0.00195	CcSEcCtD
Gonadorelin—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.00136	0.00194	CcSEcCtD
Gonadorelin—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.00136	0.00194	CcSEcCtD
Gonadorelin—Headache—Bromocriptine—type 2 diabetes mellitus	0.00134	0.00191	CcSEcCtD
Gonadorelin—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.00134	0.00191	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—type 2 diabetes mellitus	0.00133	0.00495	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—EDNRB—type 2 diabetes mellitus	0.00133	0.00494	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ARAP1—type 2 diabetes mellitus	0.00132	0.00491	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.00132	0.00188	CcSEcCtD
Gonadorelin—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.00131	0.00186	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.0013	0.00186	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—MC4R—type 2 diabetes mellitus	0.0013	0.00481	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00129	0.00185	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—HTR2C—type 2 diabetes mellitus	0.00129	0.00479	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GIPR—type 2 diabetes mellitus	0.00129	0.00478	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GRK5—type 2 diabetes mellitus	0.00129	0.00478	CbGpPWpGaD
Gonadorelin—Shock—Losartan—type 2 diabetes mellitus	0.00128	0.00183	CcSEcCtD
Gonadorelin—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00128	0.00183	CcSEcCtD
Gonadorelin—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.00128	0.00182	CcSEcCtD
Gonadorelin—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00127	0.00181	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.00127	0.00181	CcSEcCtD
Gonadorelin—Fatigue—Metformin—type 2 diabetes mellitus	0.00127	0.00181	CcSEcCtD
Gonadorelin—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.00126	0.0018	CcSEcCtD
Gonadorelin—Asthenia—Gliclazide—type 2 diabetes mellitus	0.00126	0.0018	CcSEcCtD
Gonadorelin—Constipation—Metformin—type 2 diabetes mellitus	0.00126	0.00179	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—EDNRA—type 2 diabetes mellitus	0.00126	0.00466	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AVP—type 2 diabetes mellitus	0.00125	0.00464	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GIP—type 2 diabetes mellitus	0.00125	0.00463	CbGpPWpGaD
Gonadorelin—Vomiting—Glyburide—type 2 diabetes mellitus	0.00124	0.00177	CcSEcCtD
Gonadorelin—Pruritus—Gliclazide—type 2 diabetes mellitus	0.00124	0.00177	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—ADRA2A—type 2 diabetes mellitus	0.00123	0.00456	CbGpPWpGaD
Gonadorelin—Headache—Glyburide—type 2 diabetes mellitus	0.00123	0.00175	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GHRL—type 2 diabetes mellitus	0.00122	0.00454	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VPS26A—type 2 diabetes mellitus	0.00121	0.00449	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CALCA—type 2 diabetes mellitus	0.00121	0.00449	CbGpPWpGaD
Gonadorelin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.0012	0.00171	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.0012	0.00171	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.0012	0.00171	CcSEcCtD
Gonadorelin—Fatigue—Irbesartan—type 2 diabetes mellitus	0.0012	0.00171	CcSEcCtD
Gonadorelin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00119	0.0017	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDN1—type 2 diabetes mellitus	0.00119	0.00441	CbGpPWpGaD
Gonadorelin—Pain—Irbesartan—type 2 diabetes mellitus	0.00119	0.00169	CcSEcCtD
Gonadorelin—Constipation—Irbesartan—type 2 diabetes mellitus	0.00119	0.00169	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—MC4R—type 2 diabetes mellitus	0.00118	0.00437	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.00118	0.00168	CcSEcCtD
Gonadorelin—Nausea—Glyburide—type 2 diabetes mellitus	0.00116	0.00166	CcSEcCtD
Gonadorelin—Abdominal pain—Metformin—type 2 diabetes mellitus	0.00116	0.00166	CcSEcCtD
Gonadorelin—Asthenia—Valsartan—type 2 diabetes mellitus	0.00116	0.00165	CcSEcCtD
Gonadorelin—Asthenia—Orlistat—type 2 diabetes mellitus	0.00114	0.00163	CcSEcCtD
Gonadorelin—Pruritus—Valsartan—type 2 diabetes mellitus	0.00114	0.00163	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.00113	0.00162	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GIP—type 2 diabetes mellitus	0.00113	0.0042	CbGpPWpGaD
Gonadorelin—Pruritus—Orlistat—type 2 diabetes mellitus	0.00113	0.00161	CcSEcCtD
Gonadorelin—Fatigue—Losartan—type 2 diabetes mellitus	0.00113	0.00161	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GCG—type 2 diabetes mellitus	0.00112	0.00416	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.00112	0.0016	CcSEcCtD
Gonadorelin—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00112	0.00159	CcSEcCtD
Gonadorelin—Constipation—Losartan—type 2 diabetes mellitus	0.00112	0.00159	CcSEcCtD
Gonadorelin—Pain—Losartan—type 2 diabetes mellitus	0.00112	0.00159	CcSEcCtD
Gonadorelin—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.0011	0.00158	CcSEcCtD
Gonadorelin—Shock—Ramipril—type 2 diabetes mellitus	0.0011	0.00157	CcSEcCtD
Gonadorelin—Headache—Gliclazide—type 2 diabetes mellitus	0.0011	0.00157	CcSEcCtD
Gonadorelin—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.0011	0.00157	CcSEcCtD
Gonadorelin—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.0011	0.00156	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—PIK3R1—type 2 diabetes mellitus	0.00109	0.00406	CbGpPWpGaD
Gonadorelin—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.00109	0.00156	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.00107	0.00152	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR5—type 2 diabetes mellitus	0.00106	0.00395	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—ADRB3—type 2 diabetes mellitus	0.00106	0.00394	CbGpPWpGaD
Gonadorelin—Asthenia—Metformin—type 2 diabetes mellitus	0.00106	0.0015	CcSEcCtD
Gonadorelin—Nausea—Gliclazide—type 2 diabetes mellitus	0.00104	0.00149	CcSEcCtD
Gonadorelin—Pruritus—Metformin—type 2 diabetes mellitus	0.00104	0.00148	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—C3—type 2 diabetes mellitus	0.00104	0.00386	CbGpPWpGaD
Gonadorelin—Abdominal pain—Losartan—type 2 diabetes mellitus	0.00103	0.00147	CcSEcCtD
Gonadorelin—Vomiting—Valsartan—type 2 diabetes mellitus	0.00103	0.00146	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CRHR1—type 2 diabetes mellitus	0.00102	0.0038	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.00102	0.00146	CcSEcCtD
Gonadorelin—Vomiting—Orlistat—type 2 diabetes mellitus	0.00101	0.00145	CcSEcCtD
Gonadorelin—Headache—Valsartan—type 2 diabetes mellitus	0.00101	0.00144	CcSEcCtD
Gonadorelin—Diarrhoea—Metformin—type 2 diabetes mellitus	0.00101	0.00143	CcSEcCtD
Gonadorelin—Headache—Orlistat—type 2 diabetes mellitus	0.001	0.00143	CcSEcCtD
Gonadorelin—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000996	0.00142	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGT—type 2 diabetes mellitus	0.000987	0.00366	CbGpPWpGaD
Gonadorelin—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000982	0.0014	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—type 2 diabetes mellitus	0.000979	0.00363	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000967	0.00138	CcSEcCtD
Gonadorelin—Fatigue—Ramipril—type 2 diabetes mellitus	0.000965	0.00138	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GNB3—type 2 diabetes mellitus	0.000965	0.00358	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ADRB3—type 2 diabetes mellitus	0.000963	0.00357	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000962	0.00137	CcSEcCtD
Gonadorelin—Nausea—Valsartan—type 2 diabetes mellitus	0.000959	0.00137	CcSEcCtD
Gonadorelin—Constipation—Ramipril—type 2 diabetes mellitus	0.000958	0.00137	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—MTNR1A—type 2 diabetes mellitus	0.000957	0.00355	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—AVP—type 2 diabetes mellitus	0.000952	0.00353	CbGpPWpGaD
Gonadorelin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.00095	0.00135	CcSEcCtD
Gonadorelin—Nausea—Orlistat—type 2 diabetes mellitus	0.000948	0.00135	CcSEcCtD
Gonadorelin—Desmopressin—PTGS2—type 2 diabetes mellitus	0.000941	0.0321	CrCbGaD
Gonadorelin—Asthenia—Losartan—type 2 diabetes mellitus	0.000937	0.00134	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—MTNR1B—type 2 diabetes mellitus	0.000937	0.00348	CbGpPWpGaD
Gonadorelin—Vomiting—Metformin—type 2 diabetes mellitus	0.000935	0.00133	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CRHR1—type 2 diabetes mellitus	0.00093	0.00345	CbGpPWpGaD
Gonadorelin—Pruritus—Losartan—type 2 diabetes mellitus	0.000924	0.00132	CcSEcCtD
Gonadorelin—Headache—Metformin—type 2 diabetes mellitus	0.000921	0.00131	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000916	0.00131	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—GLP1R—type 2 diabetes mellitus	0.000913	0.00339	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—EDN1—type 2 diabetes mellitus	0.000906	0.00336	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CCKAR—type 2 diabetes mellitus	0.000898	0.00333	CbGpPWpGaD
Gonadorelin—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000894	0.00127	CcSEcCtD
Gonadorelin—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000885	0.00126	CcSEcCtD
Gonadorelin—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000882	0.00126	CcSEcCtD
Gonadorelin—Nausea—Metformin—type 2 diabetes mellitus	0.000873	0.00125	CcSEcCtD
Gonadorelin—Headache—Irbesartan—type 2 diabetes mellitus	0.000869	0.00124	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	0.000851	0.00316	CbGpPWpGaD
Gonadorelin—Vomiting—Losartan—type 2 diabetes mellitus	0.00083	0.00118	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	0.000829	0.00308	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GCGR—type 2 diabetes mellitus	0.000826	0.00307	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000825	0.00118	CcSEcCtD
Gonadorelin—Nausea—Irbesartan—type 2 diabetes mellitus	0.000824	0.00118	CcSEcCtD
Gonadorelin—Headache—Losartan—type 2 diabetes mellitus	0.000818	0.00117	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	0.000816	0.00303	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	0.000813	0.00302	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CCR5—type 2 diabetes mellitus	0.00081	0.003	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	0.000809	0.003	CbGpPWpGaD
Gonadorelin—Asthenia—Ramipril—type 2 diabetes mellitus	0.000803	0.00115	CcSEcCtD
Gonadorelin—Pruritus—Ramipril—type 2 diabetes mellitus	0.000792	0.00113	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—C3—type 2 diabetes mellitus	0.000791	0.00294	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	0.00079	0.00293	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	0.000785	0.00291	CbGpPWpGaD
Gonadorelin—Nausea—Losartan—type 2 diabetes mellitus	0.000776	0.00111	CcSEcCtD
Gonadorelin—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000766	0.00109	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—GIPR—type 2 diabetes mellitus	0.00076	0.00282	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GRK5—type 2 diabetes mellitus	0.00076	0.00282	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	0.000752	0.00279	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—AGT—type 2 diabetes mellitus	0.000752	0.00279	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IAPP—type 2 diabetes mellitus	0.000734	0.00273	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	0.00073	0.00271	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	0.000717	0.00266	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	0.000713	0.00265	CbGpPWpGaD
Gonadorelin—Vomiting—Ramipril—type 2 diabetes mellitus	0.000712	0.00102	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	0.00071	0.00264	CbGpPWpGaD
Gonadorelin—Headache—Ramipril—type 2 diabetes mellitus	0.000702	0.001	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—MC4R—type 2 diabetes mellitus	0.000695	0.00258	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	0.000695	0.00258	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	0.000692	0.00257	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	0.000684	0.00254	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	0.000683	0.00253	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GIP—type 2 diabetes mellitus	0.000669	0.00248	CbGpPWpGaD
Gonadorelin—Nausea—Ramipril—type 2 diabetes mellitus	0.000665	0.000949	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	0.000663	0.00246	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	0.000645	0.00239	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—LEPR—type 2 diabetes mellitus	0.000636	0.00236	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—type 2 diabetes mellitus	0.000635	0.00235	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GCG—type 2 diabetes mellitus	0.000633	0.00235	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	0.000631	0.00234	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GHRL—type 2 diabetes mellitus	0.000628	0.00233	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	0.000623	0.00231	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CALCA—type 2 diabetes mellitus	0.000621	0.0023	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CCL2—type 2 diabetes mellitus	0.000619	0.0023	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	0.000608	0.00226	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TLE4—type 2 diabetes mellitus	0.000591	0.00219	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GCG—type 2 diabetes mellitus	0.000575	0.00213	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ADRB3—type 2 diabetes mellitus	0.000569	0.00211	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	0.000565	0.0021	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CRHR1—type 2 diabetes mellitus	0.00055	0.00204	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	0.000545	0.00202	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AVP—type 2 diabetes mellitus	0.000538	0.002	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	0.000512	0.0019	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	0.000507	0.00188	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	0.000503	0.00187	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SPRY2—type 2 diabetes mellitus	0.000503	0.00187	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GNB3—type 2 diabetes mellitus	0.000495	0.00184	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RBP4—type 2 diabetes mellitus	0.00049	0.00182	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GLP1R—type 2 diabetes mellitus	0.00049	0.00182	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AVP—type 2 diabetes mellitus	0.000489	0.00181	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—MMP3—type 2 diabetes mellitus	0.000489	0.00181	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—type 2 diabetes mellitus	0.000488	0.00181	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	0.000486	0.0018	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCKAR—type 2 diabetes mellitus	0.000482	0.00179	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EDN1—type 2 diabetes mellitus	0.000465	0.00172	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	0.000458	0.0017	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—C3—type 2 diabetes mellitus	0.000447	0.00166	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	0.000442	0.00164	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	0.000437	0.00162	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IAPP—type 2 diabetes mellitus	0.000434	0.00161	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—INSR—type 2 diabetes mellitus	0.000431	0.0016	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AGT—type 2 diabetes mellitus	0.000425	0.00158	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TRPC6—type 2 diabetes mellitus	0.000424	0.00157	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	0.000423	0.00157	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AGTR2—type 2 diabetes mellitus	0.000421	0.00156	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CCR5—type 2 diabetes mellitus	0.000416	0.00154	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—C3—type 2 diabetes mellitus	0.000406	0.00151	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EDNRB—type 2 diabetes mellitus	0.000403	0.0015	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	0.000393	0.00146	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PSMD6—type 2 diabetes mellitus	0.000392	0.00145	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HTR2C—type 2 diabetes mellitus	0.000392	0.00145	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AGT—type 2 diabetes mellitus	0.000386	0.00143	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EDNRA—type 2 diabetes mellitus	0.000381	0.00141	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CALM1—type 2 diabetes mellitus	0.000379	0.00141	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CYBA—type 2 diabetes mellitus	0.000379	0.00141	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	0.000373	0.00138	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PLAT—type 2 diabetes mellitus	0.000371	0.00138	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GHRL—type 2 diabetes mellitus	0.000371	0.00138	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CALCA—type 2 diabetes mellitus	0.000367	0.00136	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	0.000357	0.00132	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	0.000345	0.00128	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	0.000344	0.00128	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GCG—type 2 diabetes mellitus	0.00034	0.00126	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTPN1—type 2 diabetes mellitus	0.00034	0.00126	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	0.000334	0.00124	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	0.000333	0.00124	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CCL2—type 2 diabetes mellitus	0.000318	0.00118	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AKT2—type 2 diabetes mellitus	0.000312	0.00116	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	0.000312	0.00116	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	0.000295	0.0011	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GNB3—type 2 diabetes mellitus	0.000293	0.00109	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AVP—type 2 diabetes mellitus	0.000289	0.00107	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MMP3—type 2 diabetes mellitus	0.000289	0.00107	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IGF2—type 2 diabetes mellitus	0.000287	0.00107	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	0.000286	0.00106	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	0.000283	0.00105	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APOB—type 2 diabetes mellitus	0.000279	0.00104	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IGF1R—type 2 diabetes mellitus	0.000278	0.00103	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EDN1—type 2 diabetes mellitus	0.000275	0.00102	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—LPL—type 2 diabetes mellitus	0.000266	0.000989	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ADCY5—type 2 diabetes mellitus	0.000261	0.000968	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	0.00025	0.000928	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCR5—type 2 diabetes mellitus	0.000245	0.000911	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—C3—type 2 diabetes mellitus	0.00024	0.00089	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIF1A—type 2 diabetes mellitus	0.000229	0.000849	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IRS2—type 2 diabetes mellitus	0.000228	0.000847	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AGT—type 2 diabetes mellitus	0.000228	0.000846	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CALM1—type 2 diabetes mellitus	0.000224	0.000832	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—LEP—type 2 diabetes mellitus	0.000223	0.000829	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APOE—type 2 diabetes mellitus	0.000223	0.000829	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APOA1—type 2 diabetes mellitus	0.000221	0.000819	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PRKCB—type 2 diabetes mellitus	0.000211	0.000782	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IRS1—type 2 diabetes mellitus	0.000199	0.000739	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—INS—type 2 diabetes mellitus	0.000191	0.000708	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCL2—type 2 diabetes mellitus	0.000188	0.000697	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IGF1—type 2 diabetes mellitus	0.000185	0.000685	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKT2—type 2 diabetes mellitus	0.000184	0.000684	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EGFR—type 2 diabetes mellitus	0.000184	0.000681	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	0.000175	0.00065	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOS3—type 2 diabetes mellitus	0.000167	0.000621	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	0.000167	0.000621	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RELA—type 2 diabetes mellitus	0.000157	0.000584	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	0.000143	0.000532	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CASP3—type 2 diabetes mellitus	0.000142	0.000527	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL6—type 2 diabetes mellitus	0.000141	0.000524	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MMP9—type 2 diabetes mellitus	0.000134	0.000498	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	0.000133	0.000493	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	0.00013	0.000483	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SRC—type 2 diabetes mellitus	0.000124	0.000459	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	0.000121	0.000447	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	0.000111	0.000411	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGFR—type 2 diabetes mellitus	0.000108	0.000403	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL6—type 2 diabetes mellitus	8.34e-05	0.000309	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.69e-05	0.000285	CbGpPWpGaD
